Information updates

Transition from Evogam to Hizentra AU SCIg products

In May 2022, the National Blood Authority (NBA) announced that five domestically produced plasma products are undergoing transition in 2023 and 2024.

From 2 August 2023, patients on EVOGAM subcutaneous immunoglobulin (SCIg) product will transition to HIZENTRA AU, if they have not already transitioned. The timing of when each patient will transition will be determined by their treating team and it is anticipated that most patients will be transitioned by October 2023.

HIZENTRA AU will continue to be manufactured from Australia’s plasma and is approved by the Therapeutics Goods Administration (TGA) in accordance with usual high standards of safety and quality.

This NBA handout provides details and timing for the transition.

pdfHIZENTRA AU Handout 332.10 KB

This news item was issued on 26 July 2023 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand. 

Mod ASCIA Member
Donate to AIFA
go to NAC website
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia